Literature DB >> 26577289

MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours.

Firouzeh Kamali1,2, Wei-Lien Wang3, B A Guadagnolo4,5, Patricia S Fox6, Valerae O Lewis7, Alexander J Lazar3, Anthony P Conley8, Vinod Ravi8, Mohammad Toliyat9, Harshad S Ladha1, Brian P Hobbs5, Behrang Amini1.   

Abstract

OBJECTIVE: To determine the association of MRI features of extra-abdominal desmoid tumours (DTs) with prognosis.
METHODS: MRIs for 90 patients with DT were retrospectively reviewed for imaging features associated with biological behaviour. The primary end point was progression (for lesions managed with chemotherapy, radiation therapy and observation) or recurrence (following surgery). Time to event was studied using univariate and multivariable Cox proportional hazards regression models when accounting for demographic, clinicopathological and imaging variables. Kaplan-Meier plots were used to estimate event-free rate (EFR).
RESULTS: Univariate analysis revealed a significant relationship between EFR and treatment, location and compartment of origin [subcutaneous (SC), superficial fascial, intramuscular (IM) and deep fascial/intermuscular]. None of the imaging features commonly associated with biological behaviour of DTs (e.g., shape, enhancement, T2 signal etc.) or surgical margins (in surgical cases) was associated with EFR. Multivariate analysis showed that treatment modality and compartment of origin were independent predictors of EFR. Superficial and deep fascial lesions had a significantly worse EFR as a group [hazard ratio: 3.9; 95% confidence interval (CI): 1.83-8.32; p = 0.0004] than did the SC and IM lesions as a group. 5-year EFR for the fascial lesions was 18% (95% CI: 6-36%), compared with 57% (95% CI: 25-79%) for the SC and IM groups.
CONCLUSION: Intramuscular or SC DTs may be associated with improved prognosis. If validated on multireader and prospective studies, these results can provide for rapid risk stratification at the time of initial MRI. ADVANCES IN KNOWLEDGE: This work has shown that imaging features commonly associated with biological activity of desmoid tumours (e.g. shape, T2 signal and enhancement) do not appear to be associated with prognosis in patients undergoing a variety of treatment modalities. The compartment of origin of the lesion, which can be determined on pre-operative MRI, was shown to be associated with prognosis and can allow for risk stratification in patients with DTs.

Entities:  

Mesh:

Year:  2015        PMID: 26577289      PMCID: PMC4985189          DOI: 10.1259/bjr.20150308

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  32 in total

1.  Prognostic factors in desmoid-type fibromatosis: a clinicopathological and immunohistochemical analysis of 46 cases.

Authors:  Pei-Wen Huang; Chi-Yuan Tzen
Journal:  Pathology       Date:  2010-02       Impact factor: 5.306

2.  The desmoid tumor. Not a benign disease.

Authors:  M C Posner; M H Shiu; J L Newsome; S I Hajdu; J J Gaynor; M F Brennan
Journal:  Arch Surg       Date:  1989-02

3.  Ki-67 expression and residual tumour (R) classification are associated with disease-free survival in desmoid tumour patients.

Authors:  W M Brueckl; J M Preuss; A Wein; A Jung; T Brabletz; R Pflüger; G H Wiest; C Wolfl; T Kirchner; E G Hahn; W Hohenberger; K Günther
Journal:  Anticancer Res       Date:  2001 Sep-Oct       Impact factor: 2.480

4.  Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution.

Authors:  Kai Huang; Chun Meng Wang; Jing Gui Chen; Chun Yan Du; Ye Zhou; Ying Qiang Shi; Hong Fu
Journal:  Am J Surg       Date:  2013-10-09       Impact factor: 2.565

5.  Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.

Authors:  A Gronchi; P G Casali; L Mariani; S Lo Vullo; M Colecchia; L Lozza; R Bertulli; M Fiore; P Olmi; M Santinami; J Rosai
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

6.  Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.

Authors:  Sébastien Salas; Armelle Dufresne; Binh Bui; Jean-Yves Blay; Philippe Terrier; Dominique Ranchere-Vince; Sylvie Bonvalot; Eberhard Stoeckle; Louis Guillou; Axel Le Cesne; Odile Oberlin; Véronique Brouste; Jean-Michel Coindre
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

7.  A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.

Authors:  Aimeé M Crago; Brian Denton; Sébastien Salas; Armelle Dufresne; James J Mezhir; Meera Hameed; Mithat Gonen; Samuel Singer; Murray F Brennan
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

8.  Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors.

Authors:  Sylvain Briand; Olivier Barbier; David Biau; Axelle Bertrand-Vasseur; Frédérique Larousserie; Philippe Anract; François Gouin
Journal:  J Bone Joint Surg Am       Date:  2014-04-16       Impact factor: 5.284

9.  Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis.

Authors:  C Gebert; J Hardes; C Kersting; C August; H Supper; W Winkelmann; H Buerger; G Gosheger
Journal:  Histopathology       Date:  2007-03       Impact factor: 5.087

10.  [Evaluation of prognostic factors affecting recurrences and disease-free survival in extra-abdominal desmoid tumors].

Authors:  Harzem Ozger; Levent Eralp; Berkin Toker; Fulya Ağaoğlu; Yavuz Dizdar
Journal:  Acta Orthop Traumatol Turc       Date:  2007 Aug-Oct       Impact factor: 1.511

View more
  4 in total

1.  Desmoid-Type Fibromatosis-Clinical Study of an Uncommon Disease.

Authors:  Sreekanth S Kumar; K Rajeevan; E Devarajan
Journal:  Indian J Surg Oncol       Date:  2019-11-04

2.  Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.

Authors:  M Libertini; I Mitra; W T A van der Graaf; A B Miah; I Judson; R L Jones; K Thomas; E Moskovic; Z Szucs; C Benson; C Messiou
Journal:  Clin Sarcoma Res       Date:  2018-05-14

3.  MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis.

Authors:  Hui Ci Zhu; Shi Xing Xu; Xiao Ting Li; Zhen Guan; Shu Li; Ying-Shi Sun
Journal:  Front Oncol       Date:  2021-03-15       Impact factor: 6.244

4.  Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.

Authors:  Edoardo Zanchetta; Chiara Maura Ciniselli; Annalisa Bardelli; Chiara Colombo; Silvia Stacchiotti; Giacomo Giulio Baldi; Salvatore Provenzano; Rossella Bertulli; Federica Bini; Alessandra Casale; Francesca Gabriella Greco; Andrea Ferrari; Paolo Verderio; Marco Fiore; Alessandro Gronchi; Paolo Giovanni Casali; Carlo Morosi; Elena Palassini
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.